ZI-PR-1

N/A

Report date: 2025/02/14 17:42:25

Base Information

Drug NameZI-PR-1

Drug Alias NameZI-PR-1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cell replacementsMelanoma antigen preferentially expressed in tumors modulators

TargetsMelanoma antigen preferentially expressed in tumors

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZelluna Immunotherapy AS

China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A